LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.07 1.9

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.03

Max

1.1

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Aktsiakasum	-0.27
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+362.96% upside

Turustatistika
By TradingEconomics
Turukapital	-6.9M 119M
Eelmine avamishind	-0.83
Eelmine sulgemishind	1.07

Uudiste sentiment

By Acuity

72%

28%

339 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. dets 2025, 23:48 UTC

Suurimad hinnamuutused turgudel

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

8. dets 2025, 23:44 UTC

Market Talk

Perky Australian Dollar Looks to Extend Gains -- Market Talk

8. dets 2025, 23:42 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

8. dets 2025, 23:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. dets 2025, 23:13 UTC

Market Talk

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

8. dets 2025, 23:09 UTC

Omandamised, ülevõtmised, äriostud

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

8. dets 2025, 22:46 UTC

Market Talk

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

8. dets 2025, 22:01 UTC

Market Talk

Miners Poised to Do Well in 2026 -- Market Talk

8. dets 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

8. dets 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

8. dets 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

8. dets 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

8. dets 2025, 21:51 UTC

Market Talk

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

8. dets 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

8. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. dets 2025, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

8. dets 2025, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

8. dets 2025, 21:36 UTC

Market Talk

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

8. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

8. dets 2025, 21:12 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8. dets 2025, 21:08 UTC

Market Talk

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

8. dets 2025, 20:38 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

8. dets 2025, 20:26 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8. dets 2025, 20:18 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

8. dets 2025, 20:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

8. dets 2025, 20:06 UTC

Market Talk

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

8. dets 2025, 20:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8. dets 2025, 20:05 UTC

Market Talk

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

8. dets 2025, 20:01 UTC

Market Talk

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

362.96% tõus

12 kuu keskmine prognoos

Keskmine 5 USD 362.96%

Kõrge 8 USD

Madal 2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

339 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.